secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001599298-24-000043
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab shows 34% intracranial response in NSCLC brain mets; median PFS 19.3 months
--------------------------------------------------------------------------------

- Intracranial response rate 34% (23% complete) in NSCLC patients with brain metastases; median PFS 19.3 months.
- Ivonescimab + chemo in 1L squamous NSCLC: median PFS 11.1 months; non-squamous: 13.3 months; OS not reached at 22.1 months.
- No intracranial bleeding observed across cohorts; safety profile manageable with 11.1% discontinuation in squamous group.
- Two Phase III trials ongoing: HARMONi (EGFR-mutant post-TKI) and HARMONi-3 (1L squamous NSCLC).
- Data presented at ELCC 2024; posters available on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000043/0001599298-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000043/smmt-20240322.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer